ML792

Catalog No.S8697 Batch:S869701

Print

Technical Data

Formula
C21H23BrN6O5S
Molecular Weight 551.41 CAS No. 1644342-14-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (181.35 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.625mg/ml Taking the 1 mL working solution as an example, add 50 μL of 12.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ML-792 is a potent and selective inhibitor of SUMO (small ubiquitin-like modifier)-activating enzyme (SAE). ML-792 inhibits SAE/SUMO1 and SAE/SUMO2 in ATP–inorganic pyrophosphate (PPi) exchange assays with IC50 of 3 nM and 11 nM, respectively.
Targets
SAE/SUMO1 [1]
(Cell-free assay)		 SAE/SUMO2 [1]
(Cell-free assay)
3 nM 11 nM
In vitro

ML-792 is a mechanism-based SUMO-activating enzyme (SAE) inhibitor with nanomolar potency in cellular assays. ML-792 selectively blocks SAE enzyme activity and total SUMOylation, thus decreasing cancer cell proliferation. Induction of the MYC oncogene increases the ML-792-mediated viability effect in cancer cells, thus indicating a potential application of SAE inhibitors in treating MYC-amplified tumors.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HCT116 cells

  • Concentrations

    0.5 μM

  • Incubation Time

    48 h

  • Method

    HCT116 cells are plated (0.2 × 106 cells/well) and incubated overnight in six-well tissue culture dishes. To study ML-792-induced DNA damage, cells are then treated with DMSO or 0.5 μM ML-792 for 24 h. A 4-h treatment with 20 μM etoposide is used as a positive control for induction of DNA-strand breaks. To study how loss of SUMOylation contributes to repair of DNA damage by cisplatin, individual wells of HCT116 cells are treated with the following treatments: DMSO (6 h); 0.5 μM ML-792 (6 h); DMSO (2 h) followed by treatment with 10 μM cisplatin (4 h); and 0.5 μM ML-792 (2 h) followed by treatment with 10 μM cisplatin (4 h).

Selleck's ML792 has been cited by 10 publications

SUMO Promotes DNA Repair Protein Collaboration to Support Alterative Telomere Lengthening in the Absence of PML [ bioRxiv, 2024, 2024.02.29.582813] PubMed: 38463993
The SUMO-NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure [ Nat Struct Mol Biol, 2023, 10.1038/s41594-023-01045-0] PubMed: 37474739
PML and PML-like exonucleases restrict retrotransposons in jawed vertebrates [ Nucleic Acids Res, 2023, 51(7):3185-3204] PubMed: 36912092
Heat-shock protein 90α protects NME1 against degradation and suppresses metastasis of breast cancer [ Br J Cancer, 2023, 10.1038/s41416-023-02435-3] PubMed: 37731021
Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export [ Mol Carcinog, 2023, 62(5):700-715] PubMed: 36825757
SUMOylation of Nuclear γ-Actin by SUMO2 supports DNA Damage Repair against Myocardial Ischemia-Reperfusion Injury [ Int J Biol Sci, 2022, 18(11):4595-4609] PubMed: 35864967
Neddylation is essential for β-catenin degradation in Wnt signaling pathway [ Cell Rep, 2022, 38(12):110538] PubMed: 35320710
SUMOylation regulates Rb hyperphosphorylation and inactivation in uveal melanoma [ Cancer Sci, 2022, 113(2):622-633] PubMed: 34839558
Upregulation of Small Ubiquitin-Like Modifier 2 and Protein SUMOylation as a Cardioprotective Mechanism Against Myocardial Ischemia-Reperfusion Injury [ Front Pharmacol, 2021, 12:731980] PubMed: 34588985
Upregulation of Small Ubiquitin-Like Modifier 2 and Protein SUMOylation as a Cardioprotective Mechanism Against Myocardial Ischemia-Reperfusion Injury [ Front Pharmacol, 2021, 12:731980] PubMed: 34588985

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.